Physician profile
Dmitriy Timerman
NPI 1174986525
$6,616.64
in general payments reported to CMS, 2019-2025
37 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $413 · 2021: $1,022 · 2022: $619 · 2023: $1,549 · 2024: $1,151 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,186 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.41 |
| Education | $376.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.78 | 2020-2025 | Skyrizi, Natrelle Saline-Filled Breast Implants |
| Janssen Biotech, INC. | $848.32 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $578.07 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $503.89 | 2020-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $480.42 | 2020-2025 | Dupixent, Libtayo |
| Pfizer INC. | $357.91 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $301.54 | 2020-2025 | Jublia, Cabtreo |
| Incyte Corporation | $274.24 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $259.21 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $237.85 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $229.30 | 2022-2025 | |
| Ucb, INC. | $155.46 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $155.15 | 2021-2025 | |
| Endo USA, INC. | $147.55 | 2024-2025 | Xiaflex |
| Amgen INC. | $129.22 | 2022-2025 | Otezla, Otezla |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $106.88 | 2021-2023 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $87.46 | 2022-2024 | Vtama |
| Endo Pharmaceuticals INC. | $79.19 | 2022-2024 | Xiaflex |
| Organon LLC | $65.98 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $63.48 | 2023-2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $54.75 | 2020-2021 | |
| Smith+Nephew, INC. | $46.65 | 2021-2024 | Stravix, Grafix |
| Solventum Corporation | $43.80 | 2024 | Activ.A.C., Promogran Prisma, Prevena |
| Dermira, INC. | $42.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.61 | 2023 | Sotyktu |
| Genentech USA, INC. | $38.72 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $38.48 | 2020-2023 | |
| Stryker Corporation | $30.91 | 2025 | Xpress Loprofile |
| Botanix Sb INC | $24.96 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $23.73 | 2025 | Keytruda |
| Acelrx Pharmaceuticals, INC. | $22.58 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $17.60 | 2023 | Valchlor |
| Integra Lifesciences Corporation | $16.90 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Biofrontera INC. | $16.59 | 2022 | |
| Innovation Technologies INC | $15.66 | 2025 | Irrisept |
| Tela Bio, INC. | $14.01 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Baudax Bio INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Timerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.